Trial Profile

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 23 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Gemcitabine (Primary) ; Rituximab (Primary) ; Selinexor (Primary)
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors Karyopharm Therapeutics

17 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
27 Jul 2023 Planned End Date changed from 1 Aug 2024 to 1 Dec 2025.
27 Jul 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com